Monday, August 31, 2026

[WAY – Waystar] Healthcare is a very complicated invoice

Waystar sells revenue-cycle software for a US claims process where roughly 18% of submitted claims are initially denied and healthcare administration consumes 15% to 25% of spending.

WAY $4.9B

scuttleblurb Aug 31 5 clicks

Aug 27 UWMC $2B

Late August 2026 Random Ramblings

Yet Another Value Podcast 13 clicks

Aug 20 ELALF $3.2B

$ELAL: El Al is a wartime monopoly at 2x EBITDA. Is that a trap? | ASB Partners

Yet Another Value Podcast 12 clicks

From X

@irbezek Aug 22 6 clicks

Ian Bezek on X

@taobanker $INTR at 1.2x book 5.5x '27 earnings with a 16% ROE growing at 20% a year probably qualifies. But yes, $BLX is incredible and I still kick myself for selling most of my position at $25 after buying at $15. Grabbed defeat from the jaws of victory there.

@cfrischer1 Aug 19

Charles Frischer on X

@Jono8325 @MLedrappier @roadkillrecipes @CalgaryLeveen @FishOnCapital $NN Someone asked my opinion. I provided it. I am sorry if it makes you frustrated that things often take longer than we expect. It has been my life experience that things take longer than expected. That said, I am very positive on the next couple of months with NN.

@stockgutter Aug 19 2 clicks

SG on X

Good report from $BULL. I remain long and may add. https://t.co/mvOiOAN83t

@irbezek Aug 19 2 clicks

Ian Bezek on X

@LocalHero55 @OtterMarket @gatorcapital Post on an even more obscure MHC bank. And yes, $TFSL is a great income instrument, with (eventually) a chunky cap gain exit when they finally convert.

@irbezek Aug 19 2 clicks

Ian Bezek on X

@OtterMarket @gatorcapital $tfsl is just under a billion when you exclude the phantom shares. I've owned it a long time and very few people care about it either. That said, this NY one is even more obscure

@irbezek Aug 19 1 click

Ian Bezek on X

@stoked_on_waves @CapitalShipyard $open's backers also claim it is profitable. Apparently you can just say stuff now

@mavix_leon Aug 19 2 clicks

mavix on X

Shelly Group $SLYG has entered into a pan-European partnership with ALSO, Europe’s largest technology provider that provides an extensive network of resellers, system integrators and professional installers. It also supports Shelly’s international scaling strategy. https://t.co/E4Gg0SWhIA

@mavix_leon Aug 19 1 click

mavix on X

Shelly Group $SLYG major shareholder Svetlin Todorov has transferred nearly 1/4 of his shares (6.5% of Shelly) into a LLC he also owns. Maybe a preparation for a potential partial sale to Schneider Electric who would buy into Shelly as a strategic investor / partnership? https://t.co/YJfHzbSeeH

CCC Is in the Middle of the Wreckage

CCC, the dominant auto physical-damage claims estimator, connects 27 of the top 30 insurers with 31,000 repair shops as takeout rumors…

CCC $3.9B

scuttleblurb Aug 20 17 clicks

SA 2026-08-20

Seabridge Gold: Fairly Valued Now But Big Upside

Seabridge Gold's KSM gold-copper project could re-rate on a joint venture, 2027 feasibility study and infrastructure progress, with gold…

SA $3.3B

Redfern Research Aug 20

$DNOW: the boring distributor that could double on 2029 numbers | Firebird Management

DNOW’s MRC Global merger targets $75 million of synergies, with a 2029 bull case of $30 to $32 per share driven by cash flow and rerating.

DNOW $2.8B

Yet Another Value Podcast Aug 14 9 clicks

$UWMC lost $600m hedging a deal they'd already lost

UWMC booked a roughly $600 million Q2 hedging loss tied to TWO months after the deal collapsed, contributing to an expensive capital raise.

UWMC $2B

Yet Another Value Blog Aug 11 11 clicks

$CBZ: stop the buybacks and restart the M&A flywheel? | Reference Equity

CBIZ activist Ryan Bunn urges ending buybacks, issuing equity and resuming bolt-on acquisitions to delever after the $2.3 billion Marcum…

CBZ $3B

Yet Another Value Podcast Jul 14 2 clicks

$VEON: a busted EM telecom hiding a 4x? | Samit Umatiya, UIG Funds

VEON’s 84% Kyivstar stake and JazzCash underpin a sum-of-the-parts case for 4x upside, despite its sanctioned shareholder, capital…

VEON $4.8B

Yet Another Value Blog Jul 1 1 click

Under The Hood, Wingstop Inc. ($WING)

Wingstop generates most of its $697 million revenue from franchise royalties across a 3,153-restaurant, 98%-franchised system while…

WING $2.8B

Bearhold Research Jun 28 2 clicks

A Hardware Multiple on a Software Powerhouse

A software powerhouse posts a record quarter while trading at a 52-week low, raising a valuation disconnect between its business model and…

CALX $2.2B

The Value Road Jun 12 5 clicks

Vidrala

Vidrala has grown from a Spanish glass-container maker into a multi-country packaging platform with expanding Latin American exposure.

VDRFF $3.6B

smallvalue. May 19 6 clicks

AXT’s Tongmei Problem: Great Asset, Fragile Economics

AXT’s 85.5%-owned Tongmei depends on offshore pricing, export approvals and transfer-pricing economics despite AI-optics demand.

AXTI $4.2B

Maius Partners Apr 2 7 clicks

COCO · short

Vita Coco Company INC

Vita Coco, COCO, is pitched short after a 45% monthly rally, arguing investors are overextrapolating coconut water category growth.

COCO $3.5B

Value Investors Club Jun 2 1 click

BHVN 2026-08-27

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Biohaven’s $795 million global opakalim licensing deal with SK Biopharmaceuticals boosts cash, lowers R&D spending and extends its funding…

BHVN $2.1B

Edmund Ingham Aug 27 1 click

Shift4 Company Podcast Episode Released!

Shift4 built its payments business by acquiring gateway nodes and migrating merchants to its processing platform; revenue has compounded…

FOUR $3.3B

Speedwell Memos Feb 19 1 click

My Biggest Position: A Monopoly Priced for Failure

A former value-investor darling, down 50%, pairs a monopoly with a recurring-revenue razor-and-blade business; debt paydown, margin…

PBI $2.4B

Treasure Hunting Feb 5 3 clicks

Haw Par Corporation Limited

Haw Par combines Tiger Balm’s stable cash flows with property, leisure and healthcare operations plus stakes in UOB and UOL.

HAWPY $3B

smallvalue. Dec 17 4 clicks

National Beverage Update

National Beverage’s rare share repurchase is framed as a buy signal, with 50% upside projected.

FIZZ $3B

Nat Stewart - Stock Picking Newsletter Nov 25 3 clicks

Tis The (Earnings) Season

Argentine banks, tariff-exposed stocks and Customer’s Bancorp anchor an earnings-season watchlist after Milei’s election victory,…

CUBI $2.7B

Cluseau Research Oct 27 3 clicks

When extend and pretend is a virtue

Upstart says longer repayment terms lifted Q1 debt-settlement acceptances 50%, but does not disclose delinquency changes or the number of…

UPST $2.4B

John Hempton's Newsletter May 6 2 clicks

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2.2B

John Hempton's Newsletter Oct 31 1 click

[WAY – Waystar] Healthcare is a very complicated invoice

Late August 2026 Random Ramblings

$ELAL: El Al is a wartime monopoly at 2x EBITDA. Is that a trap? | ASB Partners

From X

Ian Bezek on X

Charles Frischer on X

SG on X

Ian Bezek on X

Ian Bezek on X

Ian Bezek on X

mavix on X

mavix on X

Investor Letters

CCC Is in the Middle of the Wreckage

Seabridge Gold: Fairly Valued Now But Big Upside

$DNOW: the boring distributor that could double on 2029 numbers | Firebird Management

$UWMC lost $600m hedging a deal they'd already lost

$CBZ: stop the buybacks and restart the M&A flywheel? | Reference Equity

$VEON: a busted EM telecom hiding a 4x? | Samit Umatiya, UIG Funds

Under The Hood, Wingstop Inc. ($WING)

A Hardware Multiple on a Software Powerhouse

Vidrala

AXT’s Tongmei Problem: Great Asset, Fragile Economics

Vita Coco Company INC

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Shift4 Company Podcast Episode Released!

My Biggest Position: A Monopoly Priced for Failure

Haw Par Corporation Limited

National Beverage Update

Tis The (Earnings) Season

When extend and pretend is a virtue

Sarepta Risk and the FDA

Publications we follow

YouTube 4

Blogs 12

Seeking Alpha 29 of 157

X accounts we follow

Investor letters we follow

Sectors

Monday, August 31, 2026

Ian Bezek on X

Charles Frischer on X

SG on X

Ian Bezek on X

Ian Bezek on X

Ian Bezek on X

mavix on X

mavix on X

Investor Letters

Publications we follow

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 29 of 157

X accounts we follow

Investor letters we follow

Sectors